News & Updates

T-DXd improves PFS in breast cancer with rapid progression
T-DXd improves PFS in breast cancer with rapid progression
06 Jan 2025 byStephen Padilla

Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.

T-DXd improves PFS in breast cancer with rapid progression
06 Jan 2025
Ipilimumab plus nivolumab elicits response in mCRPC
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025 byStephen Padilla

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).

Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025